MedTrace Logo

Osteopathic Approach in Inflammatory Bowel Diseases

NCT04805749 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-03-18

No results posted yet for this study

Summary

Crohn's disease (CD) and ulcerative colitis are bowel disease (IBS) with an autoimmune component believed to affect approximately 1 in 140 Canadians. Despite this high prevalence, more than 30% patients with IBD have to live with recurrent gastrointestinal symptoms that is poorly relieved by allopathic medicine. Numerous studies have shown that the quality of life of individuals with IBS is lower than that of the general population. Since visceral manipulations have been shown to be effective in reducing the main discomforts associated with IBS during clinical interventions, it seems likely that it may provide similar relief to patients with IBD. To our best knowledge, no study has evaluated the impact of osteopathic manual therapy on neuro-immuno-vascular modulation of intestine to reduce IBS symptoms.

The aim of this study is to assess the relevance of an osteopathic approach addressing the brain-intestine axis in order to improve symptomatology in subject suffering from IBD by modulating inflammation and vagal tone.

Conditions

  • Inflammatory Bowel Diseases (IBD)

Interventions

OTHER

Manual Therapy: osteopathy

Osteopathic protocol applied at week 0, 1, 2 and 3: 1. Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine. 2. Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum. 3. Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia. 4. Cranial osteopathy techniques to address the vagus parasympathetic nerves.

Sponsors & Collaborators

  • Ecole Professionnelle des Osteopathes du Quebec

    lead OTHER

Principal Investigators

  • Valérie Conway, PhD · Clinique Expertise Santé

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2021-07-01
Completion
2021-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805749 on ClinicalTrials.gov